Form 4: Avidity Biosciences Director Carsten Boess Receives Significant Equity Grant

Avidity Biosciences, Inc. Director Carsten Boess was granted 6,692 restricted stock units and 10,034 stock options, aligning his interests with shareholders.

Summary

• Carsten Boess, a Director of Avidity Biosciences, Inc. (RNA), acquired 6,692 shares of common stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, with a transaction price of $0.
• These RSUs are set to vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, contingent on Mr. Boess's continuous service.
• Additionally, Mr. Boess was granted 10,034 stock options on June 10, 2025, with an exercise price of $33.62 per share.
• These stock options will also vest in full on the earlier of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to his continuous service.
• The stock options have an expiration date of June 9, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation disclosure rather than a significant operational or financial announcement.

Positives

• The equity grants to Director Carsten Boess align his financial interests directly with those of the company's shareholders, incentivizing long-term performance.
• The grants are part of standard compensation practices for directors, indicating a structured approach to executive and board remuneration.

Future Outlook

This Form 4 filing primarily details a past equity grant and its future vesting schedule, rather than providing a general future outlook for the company's operations or financial performance.

Industry Context

Equity grants, such as Restricted Stock Units and stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. These grants are designed to attract and retain talent while aligning the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The granting of RSUs and stock options to a director is a standard practice in the biotechnology sector for executive and board compensation, aiming to incentivize long-term performance and align interests with shareholders.
• The vesting schedule, tied to continuous service and a specific future date or annual meeting, is typical for such equity awards across publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grant to a director helps align management's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation structures for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The RSUs and stock options granted to Director Carsten Boess are scheduled to vest on the first to occur of June 10, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to his continuous service.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Corporate Governance